Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for "prime time"?
出版年份 2014 全文链接
标题
Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for "prime time"?
作者
关键词
-
出版物
Hematology-American Society of Hematology Education Program
Volume 2014, Issue 1, Pages 222-233
出版商
American Society of Hematology
发表日期
2014-11-25
DOI
10.1182/asheducation-2014.1.222
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Can we say farewell to monitoring minimal residual disease in acute promyelocytic leukaemia?
- (2014) David Grimwade et al. BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
- Functional Heterogeneity of Genetically Defined Subclones in Acute Myeloid Leukemia
- (2014) Jeffery M. Klco et al. CANCER CELL
- Detection and Quantification of BCR-ABL1 Fusion Transcripts by Droplet Digital PCR
- (2014) Lawrence J. Jennings et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia
- (2014) Liran I. Shlush et al. NATURE
- Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission
- (2014) M. R. Corces-Zimmerman et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The level of residual disease based on mutant NPM1 is an independent prognostic factor for relapse and survival in AML
- (2013) N. Shayegi et al. BLOOD
- Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia
- (2013) E. Jourdan et al. BLOOD
- MRD-directed risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission: results from the AML05 multicenter trial
- (2013) H.-H. Zhu et al. BLOOD
- Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission
- (2013) R. B. Walter et al. BLOOD
- hMICL and CD123 in combination with a CD45/CD34/CD117 backbone - a universal marker combination for the detection of minimal residual disease in acute myeloid leukaemia
- (2013) Anne S. Roug et al. BRITISH JOURNAL OF HAEMATOLOGY
- Clinical significance of minimal residual disease in patients with acute leukaemia undergoing haematopoietic stem cell transplantation
- (2013) Dario Campana et al. BRITISH JOURNAL OF HAEMATOLOGY
- Leukaemia relapse after allogeneic transplants for acute myeloid leukaemia: predictive role ofWT1expression
- (2013) Sarah Pozzi et al. BRITISH JOURNAL OF HAEMATOLOGY
- Residual disease in AML, a target that can move in more than one direction
- (2013) Michael R. Loken CYTOMETRY PART B-CLINICAL CYTOMETRY
- Tumor heterogeneity makes AML a “moving target” for detection of residual disease
- (2013) W. Zeijlemaker et al. CYTOMETRY PART B-CLINICAL CYTOMETRY
- NUP98-NSD1fusion in association withFLT3-ITD mutation identifies a prognostically relevant subgroup of pediatric acute myeloid leukemia patients suitable for monitoring by real time quantitative PCR
- (2013) Susanna Akiki et al. GENES CHROMOSOMES & CANCER
- Prognostic Relevance of Treatment Response Measured by Flow Cytometric Residual Disease Detection in Older Patients With Acute Myeloid Leukemia
- (2013) Sylvie D. Freeman et al. JOURNAL OF CLINICAL ONCOLOGY
- High Prognostic Impact of Flow Cytometric Minimal Residual Disease Detection in Acute Myeloid Leukemia: Data From the HOVON/SAKK AML 42A Study
- (2013) Monique Terwijn et al. JOURNAL OF CLINICAL ONCOLOGY
- Monitoring of residual disease by next-generation deep-sequencing of RUNX1 mutations can identify acute myeloid leukemia patients with resistant disease
- (2013) A Kohlmann et al. LEUKEMIA
- Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM0902) study
- (2013) J V Jovanovic et al. LEUKEMIA
- viSNE enables visualization of high dimensional single-cell data and reveals phenotypic heterogeneity of leukemia
- (2013) El-ad David Amir et al. NATURE BIOTECHNOLOGY
- Absolute quantification by droplet digital PCR versus analog real-time PCR
- (2013) Christopher M Hindson et al. NATURE METHODS
- Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
- (2013) NEW ENGLAND JOURNAL OF MEDICINE
- Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
- (2013) Francesco Lo-Coco et al. NEW ENGLAND JOURNAL OF MEDICINE
- Normal Hematopoietic Stem Cells within the AML Bone Marrow Have a Distinct and Higher ALDH Activity Level than Co-Existing Leukemic Stem Cells
- (2013) Gerrit J. Schuurhuis et al. PLoS One
- Defining consensus leukemia-associated immunophenotypes for detection of minimal residual disease in acute myeloid leukemia in a multicenter setting
- (2013) N Feller et al. Blood Cancer Journal
- Can immunotherapy specifically target acute myeloid leukemic stem cells?
- (2013) Sylvia Snauwaert et al. OncoImmunology
- Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children's Oncology Group
- (2012) M. R. Loken et al. BLOOD
- A novel hierarchical prognostic model of AML solely based on molecular mutations
- (2012) V. Grossmann et al. BLOOD
- Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial
- (2012) J. A. L. Yin et al. BLOOD
- Prognostic and therapeutic implications of minimal residual disease at the time of transplantation in acute leukemia
- (2012) S A Buckley et al. BONE MARROW TRANSPLANTATION
- Next-generation sequencing for minimal residual disease monitoring in acute myeloid leukemia patients with FLT3-ITD or NPM1 mutations
- (2012) Felicitas Thol et al. GENES CHROMOSOMES & CANCER
- Comparative Analysis of Different Approaches to Measure Treatment Response in Acute Myeloid Leukemia
- (2012) Hiroto Inaba et al. JOURNAL OF CLINICAL ONCOLOGY
- Azacitidine fails to eradicate leukemic stem/progenitor cell populations in patients with acute myeloid leukemia and myelodysplasia
- (2012) C Craddock et al. LEUKEMIA
- The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach
- (2012) Jan J. Cornelissen et al. Nature Reviews Clinical Oncology
- Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
- (2012) Jay P. Patel et al. NEW ENGLAND JOURNAL OF MEDICINE
- A deep profiler's guide to cytometry
- (2012) Sean C. Bendall et al. TRENDS IN IMMUNOLOGY
- Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia
- (2011) F. Buccisano et al. BLOOD
- Coexistence of LMPP-like and GMP-like Leukemia Stem Cells in Acute Myeloid Leukemia
- (2011) Nicolas Goardon et al. CANCER CELL
- Diagnostic and Prognostic Value of Cytogenetics in Acute Myeloid Leukemia
- (2011) David Grimwade et al. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
- Monitoring of Minimal Residual Disease in NPM1-Mutated Acute Myeloid Leukemia: A Study From the German-Austrian Acute Myeloid Leukemia Study Group
- (2011) Jan Krönke et al. JOURNAL OF CLINICAL ONCOLOGY
- Impact of Pretransplantation Minimal Residual Disease, As Detected by Multiparametric Flow Cytometry, on Outcome of Myeloablative Hematopoietic Cell Transplantation for Acute Myeloid Leukemia
- (2011) Roland B. Walter et al. JOURNAL OF CLINICAL ONCOLOGY
- The role of multiparameter flow cytometry for disease monitoring in AML
- (2010) Wolfgang Kern et al. BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
- Towards individualized follow-up in adult acute myeloid leukemia in remission
- (2010) P. Hokland et al. BLOOD
- Leukemia-initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34- fraction
- (2010) D. C. Taussig et al. BLOOD
- Human acute myelogenous leukemia stem cells are rare and heterogeneous when assayed in NOD/SCID/IL2Rγc-deficient mice
- (2010) Jean-Emmanuel Sarry et al. JOURNAL OF CLINICAL INVESTIGATION
- Prognostic Impact of Minimal Residual Disease inCBFB-MYH11–Positive Acute Myeloid Leukemia
- (2010) Andrea Corbacioglu et al. JOURNAL OF CLINICAL ONCOLOGY
- Aberrant immunophenotype of blasts in myelodysplastic syndromes is a clinically relevant biomarker in predicting response to growth factor treatment
- (2009) T. M. Westers et al. BLOOD
- Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML
- (2009) S. Schnittger et al. BLOOD
- Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
- (2009) H. Dohner et al. BLOOD
- Real-Time Quantitative Polymerase Chain Reaction Detection of Minimal Residual Disease by StandardizedWT1Assay to Enhance Risk Stratification in Acute Myeloid Leukemia: A European LeukemiaNet Study
- (2009) Daniela Cilloni et al. JOURNAL OF CLINICAL ONCOLOGY
- Prospective Minimal Residual Disease Monitoring to Predict Relapse of Acute Promyelocytic Leukemia and to Direct Pre-Emptive Arsenic Trioxide Therapy
- (2009) David Grimwade et al. JOURNAL OF CLINICAL ONCOLOGY
- Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet
- (2008) M. A. Sanz et al. BLOOD
- Normalization of bone marrow aspirates for hemodilution in flow cytometric analyses
- (2008) Michael R. Loken et al. CYTOMETRY PART B-CLINICAL CYTOMETRY
- Development of Minimal Residual Disease–Directed Therapy in Acute Myeloid Leukemia
- (2008) Sylvie D. Freeman et al. SEMINARS IN ONCOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now